Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
The company has achieved a turnover of around Rs 100 crore in FY 2025–26 and aims to achieve a turnover of Rs 500 crore in next three years
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes
The program, which has been active for over a decade, will now expand its reach, focusing on equitable access to education, resources, and community-driven solutions for patients and care partners
The FDA approval makes PD-L1 IHC 22C3 pharmDx the only companion diagnostic approved to detect tumors expressing PD-L1 in esophageal or GEJ carcinoma patients for KEYTRUDA treatmen
Subscribe To Our Newsletter & Stay Updated
